Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Resverlogix Corp.

Healthcare CA RVX

0.09CAD
-0.005(5.26%)

Last update at 2026-06-23T15:11:00Z

Day Range

0.090.10
LowHigh

52 Week Range

0.040.30
LowHigh

Fundamentals

  • Previous Close 0.10
  • Market Cap33.20M
  • Volume38000
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.47900M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-0.04

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Income before tax -7.94265M -7.62100M -16.72600M -3.59200M -3.59200M
Minority interest - - - - -
Net income -7.90297M -7.63500M -16.74100M -3.61000M -3.61000M
Selling general administrative - 1.79M 2.77M 6.94M 6.94M
Selling and marketing expenses - - - - -
Gross profit -0.43753M -0.47675M - - -
Reconciled depreciation - 0.35M 0.72M 1.01M 1.01M
Ebit -5.20352M -4.60000M - -12.74900M -12.74900M
Ebitda -4.76600M -4.25200M - -11.74200M -11.74200M
Depreciation and amortization 0.44M 0.35M - 1.01M 1.01M
Non operating income net other - - - - -
Operating income -5.20352M -6.37032M -6.20700M -12.74900M -12.74900M
Other operating expenses 5.20M 4.65M - 12.71M 12.71M
Interest expense 4.33M 4.20M 1.83M 1.63M 1.63M
Tax provision - 0.01M 0.01M 0.02M 0.02M
Interest income - 2.65M - 9.15M 9.15M
Net interest income - -3.06600M -1.83700M -1.66900M -1.66900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.03968M 0.01M - 0.02M 0.02M
Total revenue - 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 4.77M 4.65M 6.21M 12.71M 12.71M
Cost of revenue 0.44M 0.48M - - -
Total other income expense net -2.73913M -2.97100M -8.68200M 9.16M 9.16M
Discontinued operations - - - - -
Net income from continuing ops - -7.63500M -16.74100M -3.61000M -3.61000M
Net income applicable to common shares - -7.63500M - -3.61000M -3.61000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Total assets 7.93M 7.34M 6.52M 8.12M 8.12M
Intangible assets 2.58M 2.49M 2.36M 2.21M 2.21M
Earning assets - - - - -
Other current assets 0.15M 0.04M 0.00600M 0.00800M 0.00800M
Total liab 96.73M 89.08M 80.99M 67.40M 67.40M
Total stockholder equity -88.80010M -81.73500M -74.47400M -59.28100M -59.28100M
Deferred long term liab - - - - -
Other current liab 23.22M 0.19M 0.58M 2.15M 2.15M
Common stock 334.32M - - 331.42M 331.42M
Capital stock - 334.62M 333.72M 331.42M 331.42M
Retained earnings -476.95942M -470.06200M -462.42700M -445.68600M -445.68600M
Other liab - - - - -
Good will - - - - -
Other assets - - - 2.60M 2.60M
Cash 0.11M 0.10M 0.00500M 0.04M 0.04M
Cash and equivalents - - - - -
Total current liabilities 43.98M 26.31M 26.86M 22.73M 22.73M
Current deferred revenue - - - - -
Net debt 72.66M 16.33M 6.70M 6.45M 6.45M
Short term debt 20.76M - - 6.49M 6.49M
Short long term debt - 8.30M 6.71M 6.05M 6.05M
Short long term debt total 72.77M - - 6.49M 6.49M
Other stockholder equity 53.84M - - 54.98M 54.98M
Property plant equipment - - - 0.43M 0.43M
Total current assets 1.60M 1.54M 0.52M 2.89M 2.89M
Long term investments - - - - -
Net tangible assets - - - - -
Short term investments - - - - -
Net receivables 0.91M - - 0.32M 0.32M
Long term debt - 8.13M - - -
Inventory 0.43M 1.00M 0.30M 2.37M 2.37M
Accounts payable - 16.00M 14.53M 14.10M 14.10M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - - - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 3.74M 3.32M 3.64M 2.60M 2.60M
Deferred long term asset charges - - - - -
Non current assets total 6.33M 5.81M 6.00M 5.23M 5.23M
Capital lease obligations - 0.04M 0.04M 0.44M 0.44M
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-04-30 2022-12-31
Investments - -0.37700M -0.51600M -0.47300M -0.47300M
Change to liabilities - - - -0.10200M -0.10200M
Total cashflows from investing activities -0.66036M -0.37700M - -0.47300M -0.47300M
Net borrowings - 4.38M - -0.55300M -0.55300M
Total cash from financing activities 4.39M 4.36M 3.09M 4.06M 4.06M
Change to operating activities - - - - -
Net income -7.90297M -7.63500M -16.74100M -3.61000M -3.61000M
Change in cash 0.00412M 0.09M -0.03500M 0.03M 0.03M
Begin period cash flow 0.10M 0.00500M 0.04M 0.00600M 0.00600M
End period cash flow 0.11M 0.10M 0.00500M 0.04M 0.04M
Total cash from operating activities -3.72509M -3.88600M -2.61300M -3.54100M -3.54100M
Issuance of capital stock - 0.00000M 0.28M 4.61M 4.61M
Depreciation 0.44M 0.35M 0.72M 1.01M 1.01M
Other cashflows from investing activities 0.05M 0.10M - -0.02300M -0.02300M
Dividends paid - 0.00000M - - -
Change to inventory 0.14M -0.37700M 0.00000M -0.00800M -0.00800M
Change to account receivables -0.68275M - - - -
Sale purchase of stock - - - 4.70M 4.70M
Other cashflows from financing activities - -1.63869M - 0.45M 0.45M
Change to netincome - - - - -
Capital expenditures 0.00916M 0.47M 0.45M 0.45M 0.45M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.40M -0.57100M 0.61M 4.74M 4.74M
Stock based compensation - 0.30M 1.25M 2.39M 2.39M
Other non cash items 3.34M 3.65M 1.57M -8.08300M -8.08300M
Free cash flow -3.73425M -4.35800M -3.06100M -3.99100M -3.99100M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
RVX
Resverlogix Corp.		 -0.005 5.26% 0.09 - - 1275.46 47.93 1440.16 -2.7969
EPRX
Eupraxia Pharmaceuticals Inc		 -0.23 2.45% 9.15 - - - 8.45 -3.8823
FRX
Fennec Pharmaceuticals Inc		 1.79 13.96% 14.61 - 21.01 6.95 6.35 4.25 20.27
MSCL
Satellos Bioscience Inc.		 -0.12 1.50% 7.89 - - - 5.85 6.47
HBP
Helix BioPharma Corp.		 -0.09 6.00% 1.41 - 3.87 4263.36 9.74 4422.35 -6.3589

Reports Covered

Stock Research & News

View All

Profile

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary syndrome, and post COVID-19 conditions. It has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.

Resverlogix Corp.

4820 Richard Road SW, Calgary, AB, Canada, T3E 6L1

Key Executives

Name Title Year Born
Mr. Donald J. McCaffrey Co-Founder, Chairman, Pres, CEO & Sec. NA
Mr. Aaron Bradley Cann C.A., CPA, CA, CPA, CBV Chief Financial Officer NA
Dr. Ewelina Kulikowski Ph.D. Chief Scientific Officer NA
Dr. Jan O. Johansson M.D., Ph.D. Sr. VP of Medical Affairs NA
Dr. Michael Sweeney M.D. Sr. VP of Clinical Devel. 1961
Sarah Zapotichny Director of Investor Relations & Corp. Communications NA
Mr. Aaron Bradley Cann C.A., CPA, CBV Chief Financial Officer NA
Dr. Michael Sweeney M.D. Senior Vice President of Clinical Development 1961
Mr. Donald J. McCaffrey Co-Founder, Chairman, President, CEO & Secretary NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions